|
1
|
Zang X: 2018 nobel prize in medicine
awarded to cancer immunotherapy: Immune checkpoint blockade-A
personal account. Genes Dis. 5:302–303. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xie R, Shang B, Bi X, Cao C, Guan Y, Shi H
and Shou J: Deaths and adverse events from adjuvant therapy with
immune checkpoint inhibitors in solid malignant tumors: A
systematic review and network meta-analysis. Cancer Innov.
1:293–304. 2022. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Seidel JA, Otsuka A and Kabashima K:
Anti-PD-1 and Anti-CTLA-4 therapies in cancer: Mechanisms of
action, efficacy, and limitations. Front Oncol. 8:862018.
View Article : Google Scholar
|
|
4
|
Li H, Yuan S, Wu H, Wang Y, Ma Y, Tang X,
Fu X, Zhao L, Xu B, Li T, et al: Combination therapy using low-dose
anlotinib and immune checkpoint inhibitors for extensive-stage
small cell lung cancer. Cancer Innov. 3:e1552024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao J, Zhuo X, Liu L, Yang Z and Fu G:
Opportunities and challenges of immune checkpoint inhibitors for
extensive-stage small-cell lung cancer. Cancer Innov. 1:183–193.
2022. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mao L, Yang M, Fan X, Li W, Huang X, He W,
Lin T and Huang J: PD-1/L1 inhibitors can improve but not replace
chemotherapy for advanced urothelial carcinoma: A systematic review
and network meta-analysis. Cancer Innov. 2:191–202. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rudd CE, Taylor A and Schneider H: CD28
and CTLA-4 coreceptor expression and signal transduction. Immunol
Rev. 229:12–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rowshanravan B, Halliday N and Sansom DM:
CTLA-4: A moving target in immunotherapy. Blood. 131:58–67. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim GR and Choi JM: Current understanding
of cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling in T-cell
biology and disease therapy. Mol Cells. 45:513–521. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Babamohamadi M, Mohammadi N, Faryadi E,
Haddadi M, Merati A, Ghobadinezhad F, Amirian R, Izadi Z and
Hadjati J: Anti-CTLA-4 nanobody as a promising approach in cancer
immunotherapy. Cell Death Dis. 15:172024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lynch TJ, Bondarenko I, Luft A,
Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H,
Cuillerot JM and Reck M: Ipilimumab in combination with paclitaxel
and carboplatin as first-line treatment in stage IIIB/IV
non-small-cell lung cancer: Results from a randomized,
double-blind, multicenter phase II study. J Clin Oncol.
30:2046–2054. 2012. View Article : Google Scholar
|
|
12
|
Le DT, Lutz E, Uram JN, Sugar EA, Onners
B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM and Laheru
DA: Evaluation of ipilimumab in combination with allogeneic
pancreatic tumor cells transfected with a GM-CSF gene in previously
treated pancreatic cancer. J Immunother. 36:382–389. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shiravand Y, Khodadadi F, Kashani SMA,
Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O'Byrne K and
Kulasinghe A: Immune checkpoint inhibitors in cancer therapy. Curr
Oncol. 29:3044–3060. 2022. View Article : Google Scholar
|
|
14
|
Gutic B, Bozanovic T, Mandic A, Dugalic S,
Todorovic J, Stanisavljevic D, Dugalic MG, Sengul D, Detanac DA,
Sengul I, et al: Programmed cell death-1 and its ligands: Current
knowledge and possibilities in immunotherapy. Clinics (Sao Paulo).
78:1001772023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Z, Zhang Y, Liu C, Shao J, Chen Y,
Zhu Y, Zhang L, Qin B, Kong Z, Wang X, et al: A real-world study of
immune checkpoint inhibitors in advanced triple-negative breast
cancer. Cancer Innov. 2:172–180. 2023. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun D, Xing P and Li J: PD-L1 blockade by
immune checkpoint inhibitors impairs sensitivity to osimertinib in
EGFR-mutant non-small cell lung cancer cells. Cancer Innov.
1:348–349. 2022. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y,
Wu W, Han L and Wang S: The role of PD-1/PD-L1 and application of
immune-checkpoint inhibitors in human cancers. Front Immunol.
13:9644422022. View Article : Google Scholar
|
|
18
|
Han Y, Liu D and Li L: PD-1/PD-L1 pathway:
Current researches in cancer. Am J Cancer Res. 10:727–742.
2020.PubMed/NCBI
|
|
19
|
Ai L, Xu A and Xu J: Roles of PD-1/PD-L1
pathway: Signaling, cancer, and beyond. Adv Exp Med Biol.
1248:33–59. 2020. View Article : Google Scholar
|
|
20
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar
|
|
21
|
Chikuma S: Basics of PD-1 in
self-tolerance, infection, and cancer immunity. Int J Clin Oncol.
21:448–455. 2016. View Article : Google Scholar
|
|
22
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu
K: Combination strategies with PD-1/PD-L1 blockade: Current
advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
De Velasco MA, Kura Y, Fujita K and Uemura
H: Moving toward improved immune checkpoint immunotherapy for
advanced prostate cancer. Int J Urol. 31:307–324. 2024. View Article : Google Scholar
|
|
24
|
Xue J, Liu C, Shao J, Wang L, Han Y and
Wang J and Wang J: Predictive value of neutrophil-to-lymphocyte
ratio for immune checkpoint inhibitor-related myocarditis among
patients treated for non-small-cell lung cancer. Cancer Innov.
4:e1632025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tucker L, Sacks S and Al-Mossawi H:
THU0562 Inflammatory joint disease triggered by immune checkpoint
inhibitors. Ann Rheum Dis. 76:4192017. View Article : Google Scholar
|
|
27
|
Lee DJ, Lee HJ Jr, Farmer JR and Reynolds
KL: Mechanisms driving immune-related adverse events in cancer
patients treated with immune checkpoint inhibitors. Curr Cardiol
Rep. 23:982021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Darnell EP, Mooradian MJ, Baruch EN,
Yilmaz M and Reynolds KL: Immune-related adverse events (irAEs):
Diagnosis, management, and clinical Pearls. Curr Oncol Rep.
22:392020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Melia A, Fockens E, Sfumato P, Zemmour C,
Madroszyk A, Lafforgue P and Pham T: Musculoskeletal immune-related
adverse events in 927 patients treated with immune checkpoint
inhibitors for solid cancer. Joint Bone Spine. 90:1054572023.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thapa B, Roopkumar J, Kim AS, Gervaso L,
Patil PD, Calabrese C, Khorana AA and Funchain P: Incidence and
clinical pattern of immune related adverse effects (irAE) due to
immune checkpoint inhibitors (ICI). J Clin Oncol. 37:e141512019.
View Article : Google Scholar
|
|
31
|
Jeurling S and Cappelli LC: Treatment of
immune checkpoint inhibitor-induced inflammatory arthritis. Curr
Opin Rheumatol. 32:315–320. 2020. View Article : Google Scholar
|
|
32
|
Haanen J, Carbonnel F, Robert C, Kerr KM,
Peters S, Larkin J and Jordan K; ESMO Guidelines Committee, :
Management of toxicities from immunotherapy: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28
(Suppl 4):iv119–iv142. 2017. View Article : Google Scholar
|
|
33
|
Chan KK and Bass AR: Monitoring and
management of the patient with immune checkpoint inhibitor-induced
inflammatory arthritis: Current perspectives. J Inflamm Res.
15:3105–3118. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Calabrese C, Kirchner E, Kontzias A,
Velcheti V and Calabrese LH: Rheumatic immune-related adverse
events of checkpoint therapy for cancer: Case series of a new
nosological entity. RMD Open. 3:e0004122017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cappelli LC, Gutierrez AK, Baer AN,
Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo
J, et al: Inflammatory arthritis and sicca syndrome induced by
nivolumab and ipilimumab. Ann Rheum Dis. 76:43–50. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim ST, Tayar J, Trinh VA, Suarez-Almazor
M, Garcia S, Hwu P, Johnson DH, Uemura M and Diab A: Successful
treatment of arthritis induced by checkpoint inhibitors with
tocilizumab: A case series. Ann Rheum Dis. 76:2061–2064. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Abe K, Ishikawa Y, Fujiwara M, Yukawa H,
Yanagihara T, Takei S, Arioka H and Kita Y: Immune checkpoint
inhibitor-induced refractory polyarthritis rapidly improved by
sarilumab and monitoring with joint ultrasonography: A case report.
Medicine (Baltimore). 101:e284282022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Calzascia T, Pellegrini M, Hall H, Sabbagh
L, Ono N, Elford AR, Mak TW and Ohashi PS: TNF-alpha is critical
for antitumor but not antiviral T cell immunity in mice. J Clin
Invest. 117:3833–3845. 2007. View Article : Google Scholar
|
|
39
|
Chang Q, Daly L and Bromberg J: The IL-6
feed-forward loop: A driver of tumorigenesis. Semin Immunol.
26:48–53. 2014. View Article : Google Scholar
|
|
40
|
Shinriki S, Jono H, Ota K, Ueda M, Kudo M,
Ota T, Oike Y, Endo M, Ibusuki M, Hiraki A, et al: Humanized
anti-interleukin-6 receptor antibody suppresses tumor angiogenesis
and in vivo growth of human oral squamous cell carcinoma. Clin
Cancer Res. 15:5426–5434. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
U.S. Department of Health and Human
Services, . Common terminology criteria for adverse events (CTCAE)
version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5×7.pdfOctober
31–2019
|
|
42
|
Albayda J, Dein E, Shah AA, Bingham CO III
and Cappelli L: Sonographic findings in inflammatory arthritis
secondary to immune checkpoint inhibition: A case series. ACR Open
Rheumatol. 1:303–307. 2019. View Article : Google Scholar
|
|
43
|
Smith MH and Bass AR: Arthritis after
cancer immunotherapy: Symptom duration and treatment response.
Arthritis Care Res (Hoboken). 71:362–366. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cappelli LC, Gutierrez AK, Bingham CO III
and Shah AA: Rheumatic and musculoskeletal immune-related adverse
events due to immune checkpoint inhibitors: A systematic review of
the literature. Arthritis Care Res (Hoboken). 69:1751–1763. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kostine M, Rouxel L, Barnetche T, Veillon
R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S,
Beylot-Barry M, et al: Rheumatic disorders associated with immune
checkpoint inhibitors in patients with cancer-clinical aspects and
relationship with tumour response: A single-centre prospective
cohort study. Ann Rheum Dis. 77:393–398. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Buder-Bakhaya K, Benesova K, Schulz C,
Anwar H, Dimitrakopoulou-Strauss A, Weber TF, Enk A, Lorenz HM and
Hassel JC: Characterization of arthralgia induced by PD-1 antibody
treatment in patients with metastasized cutaneous malignancies.
Cancer Immunol Immunother. 67:175–182. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lidar M, Giat E, Garelick D, Horowitz Y,
Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R and
Markel G: Rheumatic manifestations among cancer patients treated
with immune checkpoint inhibitors. Autoimmun Rev. 17:284–289. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huscher D, Thiele K, Gromnica-Ihle E, Hein
G, Demary W, Dreher R, Zink A and Buttgereit F: Dose-related
patterns of glucocorticoid-induced side effects. Ann Rheum Dis.
68:1119–1124. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Damuzzo V, Solito S, Pinton L, Carrozzo E,
Valpione S, Pigozzo J, Giancristofaro RA, Chiarion-Sileni V and
Mandruzzato S: Clinical implication of tumor-associated and
immunological parameters in melanoma patients treated with
ipilimumab. Oncoimmunology. 5:e12495592016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tachibana H, Nemoto Y, Ishihara H, Fukuda
H, Yoshida K, Iizuka J, Hashimoto Y, Kondo T, Tanabe K and Takagi
T: Predictive impact of early changes in serum C-reactive protein
levels in nivolumab plus ipilimumab therapy for metastatic renal
cell carcinoma. Clin Genitourin Cancer. 20:e81–e88. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shi Y, Liu X, Du J, Zhang D, Liu J, Chen
M, Zhao J, Zhong W, Xu Y and Wang M: Circulating cytokines
associated with clinical outcomes in advanced non-small cell lung
cancer patients who received chemoimmunotherapy. Thorac Cancer.
13:219–227. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Diehl S and Rincón M: The two faces of
IL-6 on Th1/Th2 differentiation. Mol Immunol. 39:531–536. 2002.
View Article : Google Scholar
|
|
53
|
Vilgelm AE: Illuminating the mechanism of
IL-6-mediated immunotherapy resistance. Cell Rep Med. 4:1009012023.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tsukamoto H, Fujieda K, Miyashita A,
Fukushima S, Ikeda T, Kubo Y, Senju S, Ihn H, Nishimura Y and
Oshiumi H: Combined blockade of IL6 and PD-1/PD-L1 signaling
abrogates mutual regulation of their immunosuppressive effects in
the tumor microenvironment. Cancer Res. 78:5011–5022. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kishimoto T: The biology of interleukin-6.
Blood. 74:1–10. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hirano T, Yasukawa K, Harada H, Taga T,
Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K and
Iwamatsu A: Complementary DNA for a novel human interleukin (BSF-2)
that induces B lymphocytes to produce immunoglobulin. Nature.
324:73–76. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tanaka T and Kishimoto T: The biology and
medical implications of interleukin-6. Cancer Immunol Res.
2:288–294. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tanaka T, Narazaki M and Kishimoto T: IL-6
in inflammation, immunity, and disease. Cold Spring Harb Perspect
Biol. 6:a0162952014. View Article : Google Scholar
|
|
59
|
Hirano T: IL-6 in inflammation,
autoimmunity and cancer. Int Immunol. 33:127–148. 2021. View Article : Google Scholar
|
|
60
|
Dienz O and Rincon M: The effects of IL-6
on CD4 T cell responses. Clin Immunol. 130:27–33. 2009. View Article : Google Scholar
|
|
61
|
Kimura A and Kishimoto T: IL-6: regulator
of Treg/Th17 balance. Eur J Immunol. 40:1830–1835. 2010. View Article : Google Scholar
|
|
62
|
Tanaka T, Narazaki M and Kishimoto T:
Therapeutic targeting of the interleukin-6 receptor. Annu Rev
Pharmacol Toxicol. 52:199–219. 2012. View Article : Google Scholar
|
|
63
|
Haruta H, Ohguro N, Fujimoto M, Hohki S,
Terabe F, Serada S, Nomura S, Nishida K, Kishimoto T and Naka T:
Blockade of interleukin-6 signaling suppresses not only Th17 but
also interphotoreceptor retinoid binding protein-specific Th1 by
promoting regulatory T cells in experimental autoimmune
uveoretinitis. Invest Ophthalmol Vis Sci. 52:3264–3271. 2011.
View Article : Google Scholar
|
|
64
|
Ma CS, Deenick EK, Batten M and Tangye SG:
The origins, function, and regulation of T follicular helper cells.
J Exp Med. 209:1241–1253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Feng W, Liu H, Luo T, Liu D, Du J, Sun J,
Wang W, Han X, Yang K, Guo J, et al: Combination of IL-6 and sIL-6R
differentially regulate varying levels of RANKL-induced
osteoclastogenesis through NF-κB, ERK and JNK signaling pathways.
Sci Rep. 7:414112017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Akira S, Taga T and Kishimoto T:
Interleukin-6 in biology and medicine. Adv Immunol. 54:1–78. 1993.
View Article : Google Scholar
|
|
67
|
Rose-John S: Interleukin-6 signalling in
health and disease. F1000Res. 9:F1000Faculty Rev. –1013. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Groza Y, Jemelkova J, Kafkova LR, Maly P
and Raska M: IL-6 and its role in IgA nephropathy development.
Cytokine Growth Factor Rev. 66:1–14. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hunter CA and Jones SA: IL-6 as a keystone
cytokine in health and disease. Nat Immunol. 16:448–457. 2015.
View Article : Google Scholar
|
|
70
|
Wang J, Sun Q, Zhang J, Wang H and Liu H:
Classical signaling and trans-signaling pathways stimulated by
megalobrama amblycephala IL-6 and IL-6R. Int J Mol Sci.
23:20192022. View Article : Google Scholar
|
|
71
|
Schmidt-Arras D and Rose-John S: Endosomes
as signaling platforms for IL-6 family cytokine receptors. Front
Cell Dev Biol. 9:6883142021. View Article : Google Scholar
|
|
72
|
Rose-John S: IL-6 trans-signaling via the
soluble IL-6 receptor: Importance for the pro-inflammatory
activities of IL-6. Int J Biol Sci. 8:1237–1247. 2012. View Article : Google Scholar
|
|
73
|
Song M, Wang Y, Annex BH and Popel AS:
Experiment-based computational model predicts that IL-6 classic and
trans-signaling exhibit similar potency in inducing downstream
signaling in endothelial cells. NPJ Syst Biol Appl. 9:452023.
View Article : Google Scholar
|
|
74
|
Kozłowski L, Zakrzewska I, Tokajuk P and
Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6),
interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of
breast cancer patients. Rocz Akad Med Bialymst. 48:82–84. 2003.
|
|
75
|
Shibayama O, Yoshiuchi K, Inagaki M,
Matsuoka Y, Yoshikawa E, Sugawara Y, Akechi T, Wada N, Imoto S,
Murakami K, et al: Association between adjuvant regional
radiotherapy and cognitive function in breast cancer patients
treated with conservation therapy. Cancer Med. 3:702–709. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Mori S, Murakami-Mori K and Bonavida B:
Interleukin-6 induces G1 arrest through induction of p27(Kip1), a
cyclin-dependent kinase inhibitor, and neuron-like morphology in
LNCaP prostate tumor cells. Biochem Biophys Res Commun.
257:609–614. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Klausen P, Pedersen L, Jurlander J and
Baumann H: Oncostatin M and interleukin 6 inhibit cell cycle
progression by prevention of p27kip1 degradation in HepG2 cells.
Oncogene. 19:3675–3683. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Moran DM, Mattocks MA, Cahill PA, Koniaris
LG and McKillop IH: Interleukin-6 mediates G(0)/G(1) growth arrest
in hepatocellular carcinoma through a STAT 3-dependent pathway. J
Surg Res. 147:23–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Flørenes VA, Lu C, Bhattacharya N, Rak J,
Sheehan C, Slingerland JM and Kerbel RS: Interleukin-6 dependent
induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is
lost during progression of human malignant melanoma. Oncogene.
18:1023–1032. 1999. View Article : Google Scholar
|
|
80
|
Kortylewski M, Heinrich PC, Mackiewicz A,
Schniertshauer U, Klingmüller U, Nakajima K, Hirano T, Horn F and
Behrmann I: Interleukin-6 and oncostatin M-induced growth
inhibition of human A375 melanoma cells is STAT-dependent and
involves upregulation of the cyclin-dependent kinase inhibitor
p27/Kip1. Oncogene. 18:3742–3753. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Masjedi A, Hashemi V, Hojjat-Farsangi M,
Ghalamfarsa G, Azizi G, Yousefi M and Jadidi-Niaragh F: The
significant role of interleukin-6 and its signaling pathway in the
immunopathogenesis and treatment of breast cancer. Biomed
Pharmacother. 108:1415–1424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Cathcart JM, Banach A, Liu A, Chen J,
Goligorsky M and Cao J: Interleukin-6 increases matrix
metalloproteinase-14 (MMP-14) levels via down-regulation of p53 to
drive cancer progression. Oncotarget. 7:61107–61120. 2016.
View Article : Google Scholar
|
|
83
|
Chung YC, Chen SJ, Huang CC, Liu WC, Lai
MT, Kao TY, Yang WS, Yang CH, Hsu CP and Chang JF: Tocilizumab
exerts anti-tumor effects on colorectal carcinoma cell xenografts
corresponding to expression levels of interleukin-6 receptor.
Pharmaceuticals (Basel). 17:1272024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Chonov DC, Ignatova MMK, Ananiev JR and
Gulubova MV: IL-6 activities in the tumour microenvironment. Part
1. Open Access Maced J Med Sci. 7:2391–2398. 2019. View Article : Google Scholar
|
|
85
|
Fu C, Jiang L, Hao S, Liu Z, Ding S, Zhang
W, Yang X and Li S: Activation of the IL-4/STAT6 signaling pathway
promotes lung cancer progression by increasing M2 myeloid cells.
Front Immunol. 10:26382019. View Article : Google Scholar
|
|
86
|
Huang B, Lang X and Li X: The role of
IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol.
12:10231772022. View Article : Google Scholar
|
|
87
|
Xu J, Lin H, Wu G, Zhu M and Li M:
IL-6/STAT3 is a promising therapeutic target for hepatocellular
carcinoma. Front Oncol. 11:7609712021. View Article : Google Scholar
|
|
88
|
Ando K, Takahashi F, Kato M, Kaneko N, Doi
T, Ohe Y, Koizumi F, Nishio K and Takahashi K: Tocilizumab, a
proposed therapy for the cachexia of interleukin6-expressing lung
cancer. PLoS One. 9:e1024362014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Bayliss TJ, Smith JT, Schuster M, Dragnev
KH and Rigas JR: A humanized anti-IL-6 antibody (ALD518) in
non-small cell lung cancer. Expert Opin Biol Ther. 11:1663–1668.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Fa'ak F, Buni M, Falohun A, Lu H, Song J,
Johnson DH, Zobniw CM, Trinh VA, Awiwi MO, Tahon NH, et al:
Selective immune suppression using interleukin-6 receptor
inhibitors for management of immune-related adverse events. J
Immunother Cancer. 11:e0068142023. View Article : Google Scholar
|
|
91
|
Yao X, Huang J, Zhong H, Shen N, Faggioni
R, Fung M and Yao Y: Targeting interleukin-6 in inflammatory
autoimmune diseases and cancers. Pharmacol Ther. 141:125–139. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Nagasaki T, Hara M, Nakanishi H, Takahashi
H, Sato M and Takeyama H: Interleukin-6 released by colon
cancer-associated fibroblasts is critical for tumour angiogenesis:
anti-interleukin-6 receptor antibody suppressed angiogenesis and
inhibited tumour-stroma interaction. Br J Cancer. 110:469–478.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Oguro T, Ishibashi K, Sugino T, Hashimoto
K, Tomita S, Takahashi N, Yanagida T, Haga N, Aikawa K, Suzutani T,
et al: Humanised antihuman IL-6R antibody with interferon inhibits
renal cell carcinoma cell growth in vitro and in vivo through
suppressed SOCS3 expression. Eur J Cancer. 49:1715–1724. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Wang D, Xu J, Liu B, He X, Zhou L, Hu X,
Qiao F, Zhang A, Xu X, Zhang H, et al: IL6 blockade potentiates the
anti-tumor effects of γ-secretase inhibitors in Notch3-expressing
breast cancer. Cell Death Differ. 25:330–339. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Holmstroem RB, Nielsen OH, Jacobsen S,
Riis LB, Theile S, Bjerrum JT, Vilmann P, Johansen JS, Boisen MK,
Eefsen RHL, et al: COLAR: Open-label clinical study of IL-6
blockade with tocilizumab for the treatment of immune checkpoint
inhibitor-induced colitis and arthritis. J Immunother Cancer.
10:e0051112022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Richter MD, Crowson C, Kottschade LA,
Finnes HD, Markovic SN and Thanarajasingam U: Rheumatic syndromes
associated with immune checkpoint inhibitors: A single-center
cohort of sixty-one patients. Arthritis Rheumatol. 71:468–475.
2019. View Article : Google Scholar
|
|
97
|
Abdel-Wahab N, Shah M, Lopez-Olivo MA and
Suarez-Almazor ME: Use of immune checkpoint inhibitors in the
treatment of patients with cancer and preexisting autoimmune
disease: A systematic review. Ann Intern Med. 168:121–130. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Mooradian M, Fintelmann F, Fadden R, Rubin
KM, Lawless A, Vitali M, Sharova T, Boland GM, Lawrence DP, Cohen
JV, et al: A phase II study of cryoablation (cryo) of an enlarging
tumor in patients (pts) with advanced lung cancer or melanoma
receiving post-progression immune checkpoint inhibition (ICI). J
Clin Oncol. 37:e14243. 2019. View Article : Google Scholar
|
|
99
|
Verspohl SH, Holderried T, Behning C,
Brossart P and Schäfer VS: Prevalence, therapy and tumour response
in patients with rheumatic immune-related adverse events following
immune checkpoint inhibitor therapy: A single-centre analysis. Ther
Adv Musculoskelet Dis. 13:1759720×2110069632021. View Article : Google Scholar
|
|
100
|
Ladouceur A, Barnetche T, Mouterde G,
Tison A, Bitoun S, Prey S, Dutriaux C, Gerard E, Pham-Ledard A,
Beylot-Barry M, et al: Immune checkpoint inhibitor rechallenge in
patients who previously experienced immune-related inflammatory
arthritis: A multicentre observational study. RMD Open.
9:e0037952023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Pirker I, Rubbert-Roth A, von Kempis J,
Fehr M and Neumann T: Tocilizumab in a patient with newly diagnosed
rheumatoid arthritis secondary to checkpoint inhibitor therapy.
Clin Exp Rheumatol. 38:573–574. 2020.
|
|
102
|
Mooradian MJ, Nasrallah M, Gainor JF,
Reynolds KL, Cohen JV, Lawrence DP, Miloslavsky EM, Kohler MJ,
Sullivan RJ and Schoenfeld SR: Musculoskeletal rheumatic
complications of immune checkpoint inhibitor therapy: A single
center experience. Semin Arthritis Rheum. 48:1127–1132. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Liapi M and Chatzidionysiou K: POS1356
treatment of immune checkpoint inhibitor-induced inflammatory
arthritis and polymyalgia rheumatica. Ann Rheum Dis. 81:10172022.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Saygin C, Kishtagari A, Cassaday RD,
Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL,
Tallman MS, et al: Therapy-related acute lymphoblastic leukemia is
a distinct entity with adverse genetic features and clinical
outcomes. Blood Adv. 3:4228–4237. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Hu X, Li J, Fu M, Zhao X and Wang W: The
JAK/STAT signaling pathway: From bench to clinic. Signal Transduct
Target Ther. 6:4022021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Byer SH, Stewart C, Mansour S and Grewal
US: Novel use of abatacept and ruxolitinib as salvage therapy in
steroid-refractory immune checkpoint blockade-induced myocarditis
with myasthenia and myositis overlap syndrome. Eur J Cancer.
202:1140272024. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Schust J, Sperl B, Hollis A, Mayer TU and
Berg T: Stattic: A small-molecule inhibitor of STAT3 activation and
dimerization. Chem Biol. 13:1235–1242. 2006. View Article : Google Scholar
|
|
108
|
Yue P and Turkson J: Targeting STAT3 in
cancer: How successful are we? Expert Opin Investig Drugs.
18:45–56. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Qin W, Hu L, Zhang X, Jiang S, Li J, Zhang
Z and Wang X: The diverse function of PD-1/PD-l pathway beyond
cancer. Front Immunol. 10:22982019. View Article : Google Scholar
|
|
110
|
Raptopoulou AP, Bertsias G, Makrygiannakis
D, Verginis P, Kritikos I, Tzardi M, Klareskog L, Catrina AI,
Sidiropoulos P and Boumpas DT: The programmed death 1/programmed
death ligand 1 inhibitory pathway is up-regulated in rheumatoid
synovium and regulates peripheral T cell responses in human and
murine arthritis. Arthritis Rheum. 62:1870–1880. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kong EKP, Prokunina-Olsson L, Wong WHS,
Lau CS, Chan TM, Alarcón-Riquelme M and Lau YL: A new haplotype of
PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese.
Arthritis Rheum. 52:1058–1062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Bommarito D, Hall C, Taams LS and
Corrigall VM: Inflammatory cytokines compromise programmed cell
death-1 (PD-1)-mediated T cell suppression in inflammatory
arthritis through up-regulation of soluble PD-1. Clin Exp Immunol.
188:455–466. 2017. View Article : Google Scholar
|
|
113
|
Huseni MA, Wang L, Klementowicz JE, Yuen
K, Breart B, Orr C, Liu LF, Li Y, Gupta V, Li C, et al:
CD8+T cell-intrinsic IL-6 signaling promotes resistance
to anti-PD-L1 immunotherapy. Cell Rep Med. 4:1008782023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Yu Y, Wang S, Su N, Pan S, Tu B, Zhao J,
Shen Y, Qiu Q, Liu X, Luan J, et al: Increased circulating levels
of CRP and IL-6 and decreased frequencies of T and B lymphocyte
subsets are associated with immune-related adverse events during
combination therapy with PD-1 inhibitors for liver cancer. Front
Oncol. 12:9068242022. View Article : Google Scholar
|
|
115
|
McArthur GA and Ribas A: Targeting
oncogenic drivers and the immune system in melanoma. J Clin Oncol.
31:499–506. 2013. View Article : Google Scholar
|
|
116
|
Shimabukuro-Vornhagen A, Gödel P, Subklewe
M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B and von
Bergwelt-Baildon MS: Cytokine release syndrome. J Immunother
Cancer. 6:562018. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Baran P, Hansen S, Waetzig GH, Akbarzadeh
M, Lamertz L, Huber HJ, Ahmadian MR, Moll JM and Scheller J: The
balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R),
and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and
trans-signaling. J Biol Chem. 293:6762–6775. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Lee DW, Gardner R, Porter DL, Louis CU,
Ahmed N, Jensen M, Grupp SA and Mackall CL: Current concepts in the
diagnosis and management of cytokine release syndrome. Blood.
124:188–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Hailemichael Y, Johnson DH, Abdel-Wahab N,
Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C,
Ogata D, et al: Interleukin-6 blockade abrogates immunotherapy
toxicity and promotes tumor immunity. Cancer Cell. 40:509–523.e506.
2022. View Article : Google Scholar
|
|
120
|
Mihara M, Ohsugi Y and Kishimoto T:
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for
treatment of rheumatoid arthritis. Open Access Rheumatol. 3:19–29.
2011. View Article : Google Scholar
|
|
121
|
Bystrom J, Taher TE, Henson SM, Gould DJ
and Mageed RA: Metabolic requirements of Th17 cells and of B cells:
Regulation and defects in health and in inflammatory diseases.
Front Immunol. 13:9907942022. View Article : Google Scholar
|
|
122
|
Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J
and Zhang L: B cells in rheumatoid arthritis: Pathogenic mechanisms
and treatment prospects. Front Immunol. 12:7507532021. View Article : Google Scholar
|
